Tandem Diabetes Care (TNDM) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Tandem Diabetes Care published the results on November 5, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison.

• From the first quarter of 2026 Tandem sells some U.S. pumps through a pay-as-you-go pharmacy model, in which a pump ships with no upfront reimbursement and Tandem is paid through higher supply prices. That lowers pump sales in the period of shipment.
• Tandem reports no adjusted EPS. Its non-GAAP net loss equalled its GAAP net loss in Q3 2026 and Q3 2025.

Source: Tandem Diabetes Care Q3 2026 results, November 5, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Tandem Diabetes Care splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Tandem Diabetes Care's United States revenue was $191 million in Q3 2026, up 9% from $176 million in Q3 2025, 67% of total revenue.
• Tandem Diabetes Care's International revenue was $92.6 million in Q3 2026, up 26% from $73.6 million in Q3 2025, 33% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

Tandem reaffirmed its full-year 2026 guidance in this release. It also guided international sales of about $335 million to $340 million.

In its Q3 2026 release, Tandem Diabetes Care said:

“Sales are estimated to be approximately $1.065 billion to $1.085 billion”

“U.S. sales of approximately $730 million to $745 million”

“Gross margin is estimated to be approximately 56% to 57% of sales”

“Adjusted EBITDA margin (2) is estimated to be approximately 5% to 6% of sales”

Source: Tandem Diabetes Care Q3 2026 release, Nov 5, 2026.

This is the company's own guidance as of Nov 5, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the TNDM forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

Sales in millions and GAAP diluted net loss per share, each as first reported in that quarter's release.

We do not hold a confirmed date for Tandem Diabetes Care's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 5, 2026

Tandem Diabetes Care sells insulin pumps (the Tandem Mobi and the t:slim X2, both running Control-IQ+) and the supplies that go with them. In Q3 2026 supplies and other made up $168.7 million of sales of $283.7 million, and pumps $115.0 million. Worldwide sales rose 14%, and Tandem shipped about 33,000 pumps. (Tandem Diabetes Care Q3 2026 release, Nov 5, 2026; Tandem Diabetes Care Form 10-Q, Q3 2026, Nov 5, 2026)

U.S. sales rose 9% to $191.0 million. Tandem said the increase came from higher volumes and the shift to its pharmacy pay-as-you-go model, which lowers the average selling price of a pump and raises supply prices. U.S. pump sales dipped to $83.4 million from $84.8 million while U.S. supplies and other rose to $107.7 million from $90.8 million. Pharmacy accounted for 15% of U.S. sales, against 5% a year earlier. (Tandem Diabetes Care Q3 2026 release, Nov 5, 2026; Tandem Diabetes Care Form 10-Q, Q3 2026, Nov 5, 2026)

International sales grew 26% to $92.6 million, or 27% in constant currency, on nearly 11,000 pump shipments. Direct sales to customers made up 18% of international sales, against 3% a year earlier, as Tandem begins international direct operations. (Tandem Diabetes Care Q3 2026 release, Nov 5, 2026; Tandem Diabetes Care Form 10-Q, Q3 2026, Nov 5, 2026)

The 10-Q says overall sales growth came from higher volumes, favorable channel mix and better pricing despite a continued inventory constraint at a key supplier. Tandem says pharmacy formulary coverage reached about 50% of U.S. lives. (Tandem Diabetes Care Form 10-Q, Q3 2026, Nov 5, 2026; Tandem Diabetes Care Q3 2026 release, Nov 5, 2026)

Tandem Diabetes Care lost $(0.10) a share in Q3 2026, against $(0.31) a year earlier, on a net loss of $7.1 million. Tandem does not publish adjusted EPS; it reports adjusted EBITDA, which was $18.0 million, or 6% of sales, after adding back $15.9 million of stock-based compensation and $4.5 million of depreciation and amortization. (Tandem Diabetes Care Q3 2026 release, Nov 5, 2026)

Gross margin rose to 57% from 54%, and the operating loss narrowed to $2.4 million from $22.9 million as operating expenses rose only to $162.8 million from $157.2 million. Other expense, net, grew to $5.3 million from $2.3 million. (Tandem Diabetes Care Q3 2026 release, Nov 5, 2026)

During 2026 Tandem issued convertible senior notes due 2032, raising $291.2 million net of costs, and long-term convertible notes on the balance sheet rose to $603.4 million. It also put CHF 64.0 million ($81.4 million) more into CeQur SA, lifting the equity method investment to $125.5 million. Weighted average shares were 69.7 million. (Tandem Diabetes Care Form 10-Q, Q3 2026, Nov 5, 2026; Tandem Diabetes Care Q3 2026 release, Nov 5, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Tandem Diabetes Care guides for the full year and reaffirmed it in this release: 2026 sales of about $1.065 billion to $1.085 billion, of which U.S. sales of about $730 million to $745 million and international about $335 million to $340 million, gross margin of 56% to 57% and adjusted EBITDA margin of 5% to 6%. (Tandem Diabetes Care Q3 2026 release, Nov 5, 2026)

Through the first nine months Tandem had sales of $785.5 million. The guidance also includes about $85 million of non-cash charges, of which about $65 million is stock-based compensation. (Tandem Diabetes Care Q3 2026 release, Nov 5, 2026)

A consensus figure is the average of the models published by the analysts who cover Tandem Diabetes Care, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Tandem Diabetes Care's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning TNDM is on is TNDM a buy or a sell?, what analysts expect next is on the TNDM forecast, and what the company does is on the Tandem Diabetes Care (TNDM) stock page.

Every number on this page can be traced to a document Tandem Diabetes Care published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.